Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increase in diagnosis rate of spinal muscular atrophy in infants and children
3.2.1.2 Advancement in gene therapy
3.2.1.3 Growing awareness and screening programs by healthcare providers
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory approval for new treatments
3.2.2.2 High cost of treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Pipeline analysis
3.7 Porter’s analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Werdnig-Hoffmann disease
5.3 Infant SMA
5.4 Kugelberg-Welander disease
5.5 Adult SMA
Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Medication
6.2.1 Gene therapy
6.2.2 Antisense oligonucleotide
6.2.3 Other medications
6.3 Supportive care
6.3.1 Physical therapy
6.3.2 Respiratory support
6.3.3 Nutritional support
6.4 Spinal surgery
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Parenteral
Chapter 8 Market Estimates and Forecast, By End-Use, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospitals
8.3 Specialty clinics
8.4 Homecare settings
8.5 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 American Physical Therapy Association
10.2 Astellas Pharma
10.3 Beijing Jinlan Gene Technology Co., Ltd.
10.4 Biogen Inc.
10.5 Boston's Children Hospital
10.6 Children's Hospital of The King's Daughters
10.7 F. Hoffmann-La Roche Ltd.
10.8 Hanugen Therapeutics
10.9 Nationwide Children’s Hospital
10.10 NMD Pharma A/S
10.11 Novartis AG
10.12 Pfizer, Inc.
10.13 Sanofi (Genzyme Corporation)
10.14 Scholar Rock, Inc
